Table 1 Public funding for olaparib, by stage of R&D and availability of funding information
From: Counting the cost of public and philanthropic R&D funding: the case of olaparib
| Â | Number of studies receiving public funding (as a % of all studies) | Number of studies where public contribution was quantifiable (as a % of all publicly funded studies) | Value of public project funding that could be identified |
|---|---|---|---|
Research named in patents | 71/112 (63%) | 16/71 (23%) | $143,696,353.00  + €13,354,856.00  + Jap Yen ¥117,000,000.00 |
Pre-clinical research | 9/10 (90%) | 4/9 (44%) | $5,507,789.00  + €8,707,358.00 |
Clinical trials (phases I to III) | 3/13 (23%) | 0/3 (0%) | -Â (only a center funding grant of $25 million p.a identified through 1 publication.) |
Total in common GBP £ currency ($ and €) |  |  | £ 128,122,052.50 ($ 176,500,967.70 or € 148,530,086.30) |